FIELD: chemistry.
SUBSTANCE: invention relates to novel compounds of formulas (1C):
(1C) or a pharmaceutically acceptable salt thereof, where: n is equal to 1; Y is selected from a group consisting of a bond, -CH2-, -CO-, -SO2-, and -COCON(R8)-; wherein R8 is H, or C1-C3 alkyl; and R7 is selected from the group consisting of H, C1-C3 alkyl, C3 cycloalkyl, and 6-member heteroaryl containing 1-2 N heteroatoms, optionally substituted with a halogen;
(1AA) or a pharmaceutically acceptable salt thereof, where: m is equal to 0, 1, 2 or 3; Ra, Rb, Rc and Rd are independently selected from a group consisting of H, halogen, OCH2CF3, OH, NMe2, R3 and OR3; wherein R3 is C1-C3 alkyl group or C3 cycloalkyl group; or Ra and Rb together with a carbon atom bonded thereto, form a C3 cycloalkyl group or 4–6-membered non-aromatic heterocycle containing 1 N heteroatom, optionally substituted CH3 or COCH3; or Rc and Rd together with a carbon atom bonded to them, form a C3-C6 cycloalkyl group or 4–6-membered non-aromatic heterocycle containing 1 N or O heteroatom, optionally substituted CH3 or COCH3; or Ra (or Rb) and Rc (or Rd) together with the C-C bond bonded thereto, form C3-C6 cycloalkyl;
(1AB) or a pharmaceutically acceptable salt thereof, where: n is 1 or 2; Re and Rf are independently selected from a group consisting of H, OCH2CF3, OCH2CH2OCH3, O-CD3, R3 and OR3; wherein R3 is C1-C3 alkyl, or C3 cycloalkyl;
(1AC) or a pharmaceutically acceptable salt thereof, where: M is -O-, -NR3- or -CO-, wherein R3 is C1-C3 alkyl or COCH3; Rg, Rh, Ri and Rj are H; or Rg and Rh together represent a -CO- group; or Ri and Rj together represent a -CO- group, or Ri and Rj together with the carbon atom bonded thereto form C3 cycloalkyl;
(1BA) or a pharmaceutically acceptable salt thereof, where: n is 1 or 2; Q is -CH2- or -CO-; R9 is selected from the group consisting of H, C1-C3 alkyl, deuterated C1-C3 alkyl, C3-C6 cycloalkyl, amino-substituted C1-C3 alkylamino, C1-substituted C1-C3 alkyl, C3 substituted C1-C3 alkyl, 6-member heteroaryl and 5–7-member non-aromatic heterocycle containing 1 heteroatom N, optionally substituted with CH3.
EFFECT: novel compounds which can be used to treat or prevent diseases associated with physiological conditions associated with the CRM1 protein are obtained.
7 cl, 2 dwg, 7 tbl, 108 ex
Title | Year | Author | Number |
---|---|---|---|
TRIAZOLE DERIVATIVE, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2022 |
|
RU2832307C2 |
SUBSTITUTED MORPHOLINES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD OF COUNTERACTION TO SUBSTANCE P OR INHIBITION OF NEUROKININ-1 RECEPTORS | 1995 |
|
RU2170233C2 |
SUBSTITUTED MORPHOLINE DERIVATIVES, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION BASED ON SAID, METHOD OF DECREASE OF TACHIKININ LEVEL IN TREATMENT OR PROPHYLAXIS OF PHYSIOLOGICAL STATES ASSOCIATED WITH TACHIKININ EXCESS | 1994 |
|
RU2131426C1 |
MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | 2014 |
|
RU2650498C2 |
MONOACYLGLYCEROL LIPASE MODULATORS | 2019 |
|
RU2797323C2 |
PESTICIDE COMPOSITIONS AND METHODS RELATING THERETO | 2012 |
|
RU2596946C2 |
SUBSTITUTED HETEROCYCLES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALT, PHARMACEUTICAL COMPOSITION FOR BLOCKADE OF NEUROKININ-1 RECEPTORS IN MAMMALS, METHOD OF BLOCKADE OF NEUROKININ-1 RECEPTORS IN MAMMALS | 1993 |
|
RU2140914C1 |
1,2,4-TRIAZINE-3-AMINE DERIVATIVES | 2011 |
|
RU2771819C2 |
DIPHENYL HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD OF TREATMENT | 1997 |
|
RU2175319C2 |
PESTICIDAL COMPOSITIONS AND METHODS RELATED THERETO | 2013 |
|
RU2667788C2 |
Authors
Dates
2025-04-16—Published
2020-02-25—Filed